Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Inflammation × Atorvastatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 8 Prostatic Neoplasms 4 Cardiotoxicity 3 Heart Failure 2 Glioblastoma 2 Endometrial Neoplasms 2 Endometrial Hyperplasia 2 Triple Negative Breast Neoplasms 1 Rectal Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Polycystic Ovary Syndrome 1 Overall Survival 1 Neoplastic Cells, Circulating 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia 1 Kidney Neoplasms 1 Inflammatory Breast Neoplasms 1 Inflammation 1 Heart Diseases 1 Hearing Loss 1 Head and Neck Neoplasms 1 Erectile Dysfunction 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Colitis, Ulcerative 1 Carotid Stenosis 1

Interventions

XENP 1595 2 salicylsalicylic acid 1 microcrystalline cellulose 1 ginger extract 1 epigallocatechin gallate 1 dapagliflozin 1 Tablets 1 Sulindac 1 Specimen Handling 1 Sodium Salicylate 1 Radiotherapy, Conformal 1 Pregabalin 1 Omeprazole 1 Losartan 1 Ketorolac 1 Interleukin 1 Receptor Antagonist Protein 1 Infliximab 1 Etanercept 1 Atorvastatin 1 Ascorbic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01821404 2018-05-07

ESTO1

Tampere University Hospital

Phase 2 Completed

Inflammation, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡